Get startedLog in
    Picture of Kyverna Therapeutics logo

    KYTX — Kyverna Therapeutics News Story

    0.000.00%
    us flag iconLast trade - 00:00
    HealthcareSpeculativeSmall CapMomentum Trap
    All News

    Brief: Kyverna Therapeutics Announces Positive Topline Data From Registrational Kysa-8 Trial Of Miv-Cel (Kyv-101) In Stiff Person Syndrome

    Picture of Kyverna Therapeutics logoKyverna Therapeutics
    15/12/2025 11:36
    Dec 15 (Reuters) - Kyverna Therapeutics Inc KYTX.O:

KYVERNA THERAPEUTICS ANNOUNCES POSITIVE TOPLINE DATA FROM REGISTRATIONAL KYSA-8 TRIAL OF MIV-CEL (KYV-101) IN STIFF PERSON SYNDROME

KYVERNA THERAPEUTICS INC - MIV-CEL WELL-TOLERATED WITH NO HIGH-GRADE CRS OR ICANS

KYVERNA THERAPEUTICS INC - TO SUBMIT BLA TO FDA FOR SPS IN 1H 2026

KYVERNA THERAPEUTICS INC - MIV-CEL ACHIEVES SIGNIFICANT CLINICAL BENEFIT AFTER ONE DOSE

Source text: ID:nGNX8JNdl2

Further company coverage: KYTX.O

 ((Reuters.Briefs@thomsonreuters.com;))

    Recent news on Kyverna Therapeutics

    See all news